Gemtuzumab ozogamicin
- Generic Name
- Gemtuzumab ozogamicin
- Brand Names
- Mylotarg
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 220578-59-6
- Unique Ingredient Identifier
- 8GZG754X6M
- Background
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody . The antibody ...
- Indication
Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial tr...
- Associated Conditions
- Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)
- Associated Therapies
- -
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT03531918
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03390296
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 700
- Registration Number
- NCT02724163
- Locations
- 🇦🇺
Monash Children's Hospital, Melbourne, Australia
🇦🇺Women and Children's Hospital Adelaide, Adelaide, Australia
🇦🇺Queensland Children's Hospital, Brisbane, Australia
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 25
- Registration Number
- NCT02221310
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
SCT Plus Immune Therapy in Average Risk AML/MDS
- Conditions
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 26
- Registration Number
- NCT02117297
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Promyelocytic Leukemia (M3)Childhood Acute Promyelocytic Leukemia (M3)Recurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid Leukemia
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT01869803
- Locations
- 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With Del(5q)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Promyelocytic Leukemia (M3)
- Interventions
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT01548911
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 151
- Registration Number
- NCT01409161
- Locations
- 🇺🇸
MD Anderson Regional Care Center-Bay Area, Nassau Bay, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson Regional Care Center-Katy, Houston, Texas, United States
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 18
- Registration Number
- NCT01020539
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 71
- Registration Number
- NCT00968071
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.